eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Aberrant activation of the mechanistic target of rapamycin (mTOR) signaling pathway drives protein synthesis and tumor development.
• Targeting translation initiation presents a therapeutic strategy for mTOR-associated diseases.

Purpose of the Study:

• To evaluate the efficacy of eFT226, a selective inhibitor of eukaryotic initiation factor 4A (eIF4A)-mediated translation.
• To assess eFT226's potential in treating cells with hyperactive mTOR signaling due to tuberous sclerosis complex 1/2 (TSC1/2) or phosphatase and TENsin homology (PTEN) loss.

Main Methods:

• Utilized cell models with deficiencies in TSC1/2 or PTEN to mimic mTOR hyperactivity.
• Administered eFT226 to assess its impact on cell proliferation, cell cycle progression, and tumor development.
• Investigated the mechanisms of action, including induction of necroptosis and cell cycle arrest.

Main Results:

• eFT226 demonstrated preferential inhibition of proliferation in Tsc2- and Pten-deficient cells.
• Treatment with eFT226 induced necroptosis and G2/M phase arrest in targeted cells.
• eFT226 effectively suppressed tumor development in a TSC2-deficient model.

Conclusions:

• eFT226 is a potent inhibitor of eIF4A-mediated translation.
• eFT226 exhibits significant anti-proliferative and anti-tumor effects in models of mTOR hyperactivity.
• eFT226 represents a promising therapeutic candidate for treating mTOR-mediated tumors.